Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019)
Bicycle Therapeutics' (BCYC) quarterly Preferred Stock Liabilities came in at $54.6 million in Q1 2019, little changed YoY from $54.6 million in Q1 2018, and little changed on a QoQ basis from $54.6 million in Q4 2018.
Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Bicycle Therapeutics (BCYC) has 2 years of Preferred Stock Liabilities data on file, last reported at $54.6 million in Q1 2019.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $54.6 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $54.6 million (changed 0.0% YoY) and the FY2018 annual result came in at $54.6 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $54.6 million in Q1 2019, from $54.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $54.6 million in Q1 2018 to a low of $54.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 27.34 Mn |
| Dec 31, 2018 | 41.82 Mn |
| Jun 30, 2018 | 41.82 Mn |
| Mar 31, 2018 | 41.82 Mn |